Current development of adeno-associated viral vectors

Area of Science:

• Biotechnology
• Gene Therapy
• Virology

Background:

• Adeno-associated virus (AAV) vectors are increasingly utilized in clinical trials for neurological conditions like Parkinson's disease and Canavan's disease.
• AAV-mediated gene transfer is a key technology for delivering therapeutic genes to the central and peripheral nervous systems.
• Clinical applications extend to cystic fibrosis and hemophilia B, demonstrating broad therapeutic potential.

Purpose of the Study:

• To review the current progress, advantages, and limitations of adeno-associated virus (AAV)-based vector systems in gene therapy.
• To highlight the potential of AAV vectors while addressing critical design challenges.
• To discuss the future perspectives and drawbacks associated with AAV-derived vectors.

Main Methods:

• Literature review of preclinical and clinical studies involving AAV-based gene transfer.
• Analysis of AAV vector applications in various disease models and human trials.
• Evaluation of AAV vector capacity and safety profiles, including insertional mutagenesis.

Main Results:

• AAV vectors have demonstrated success in early-phase clinical trials for neurological and genetic disorders.
• Significant advancements have been made in AAV vector development.
• Limitations include restricted capacity for foreign gene accommodation and potential oncogenesis due to insertional mutagenesis in preclinical studies.

Conclusions:

• AAV-mediated gene transfer is a powerful tool with considerable therapeutic promise.
• Further improvements in AAV vector design are essential to overcome current limitations.
• Addressing safety concerns, such as insertional mutagenesis, is crucial for the advancement of AAV-based therapies.